Nothing Special   »   [go: up one dir, main page]

Wandinger et al., 2000 - Google Patents

Association between clinical disease activity and Epstein–Barr virus reactivation in MS

Wandinger et al., 2000

Document ID
1783566828690310196
Author
Wandinger K
Jabs W
Siekhaus A
Bubel S
Trillenberg P
Wagner H
Wessel K
Kirchner H
Hennig H
Publication year
Publication venue
Neurology

External Links

Snippet

Objective: To assess the potential significance of Epstein–Barr virus (EBV) reactivation in disease activity in MS patients. Methods: The prevalence of antibodies against herpes simplex virus type 1 (HSV-1), HSV-2, EBV, and cytomegalovirus was determined in a group …
Continue reading at www.neurology.org (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses

Similar Documents

Publication Publication Date Title
Wandinger et al. Association between clinical disease activity and Epstein–Barr virus reactivation in MS
Guan et al. The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to: in vivo: imaging
Ruprecht The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review
Guihot et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma
Ambalathingal et al. BK polyomavirus: clinical aspects, immune regulation, and emerging therapies
Lünemann et al. Elevated Epstein–Barr virus‐encoded nuclear antigen‐1 immune responses predict conversion to multiple sclerosis
Agostini et al. HLA alleles modulate EBV viral load in multiple sclerosis
Lünemann et al. Epstein-barr virus: environmental trigger of multiple sclerosis?
Jaquiéry et al. Intrathecal immune responses to EBV in early MS
Schachtner et al. BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy
Coaquette et al. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients
Laska et al. Expression of HERV-Fc1, a human endogenous retrovirus, is increased in patients with active multiple sclerosis
Nastke et al. Human CD4+ T cell response to human herpesvirus 6
Du Pasquier et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals
Yea et al. Epstein-Barr virus in oral shedding of children with multiple sclerosis
Morris et al. Do human endogenous retroviruses contribute to multiple sclerosis, and if so, how?
Du Pasquier et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-A* 0201-restricted JC virus epitope VP1p36 in patients with proven or possible progressive multifocal leukoencephalopathy
Tejada-Simon et al. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls
Christensen The role of EBV in MS pathogenesis
Yao et al. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients
Tao et al. Association between human herpesvirus & human endogenous retrovirus and MS onset & progression
Norbeck et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans
Cuomo et al. Elevated antinuclear antibodies and altered anti-Epstein-Barr virus immune responses
Meinl Concepts of viral pathogenesis of multiple sclerosis
Monteyne et al. Viruses and multiple sclerosis